

# Phosphorothioate oligonucleotides can displace *NEAT1 RNA* to form nuclear paraspeckle-like structures

## SUPPLEMENTARY DATA

### SUPPLEMENTAL MATERIALS AND METHODS

#### siRNAs:

P54nrb (s9612 and s9614), PSPC1 (s30594), hnRNPK (s6737), LRPPRC (HSS115403), and KHSRP (HSS112552) siRNAs were purchased from Life Technologies. NCL1 siRNA (S9312) was purchased from Ambion.

#### Antibodies:

Anti-PSPC1 (ab104238), anti-hnRNP K (ab32969), anti-Fibrillarin (ab5821), anti-TCP1- $\beta$  (ab92746), embryonic stem cell marker panel (ab109884) antibodies were purchased from Abcam. Anti-P54nrb (sc-376865) antibody for western analysis and IF was purchased from Santa Cruz Biotechnology. Anti-P54nrb (05-950) antibody for RIP (Fig.6 H) was purchased from EMD Millipore. Anti-PSF (P2860) and anti-GAPDH (G8795) were purchased from Sigma. Anti-RNase H1 antibody was kindly provided by Hongjiang Wu. Anti-rabbit secondary antibody conjugated to HRP (170-6515) and anti-mouse secondary antibody conjugated to HRP (170-6516) were purchased from Bio-Rad. Anti-rabbit secondary antibodies conjugated to AF488 (ab150077), AF555 (ab150078), and AF647 (ab150079), as well as anti-mouse secondary antibodies conjugated to AF488 (ab150113), AF555 (ab150114), and AF647 (ab150115) were purchased from Abcam.

#### Plasmids:

GFP-tagged P54nrb (RG226567) plasmid was purchased from ORIGENE. Plasmid transfection was performed using Effectene Transfection Reagent (QIAGEN), according to manufacturer's instructions.

#### ASOs:

In the tables below, deoxyribonucleotides are in plain font, ribonucleotides are underlined, and 2'-modified ribonucleotides are indicated in bold. Phosphorothioate (PS) backbone residues are indicated in italic.

**Table 1. ASOs for protein isolation**

Figure	ASO	Sequence	2' Modification
1A, B, and C	Capture	ISIS386652: 5'- biotin – <b>CTGCTAGCCTCTGGATTGA</b> -3'	MOE
	Elution	ISIS116847: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	MOE
1D	Capture	ISIS586183: 5'- biotin – <b>CTGCTAGCCTCTGGATTGA</b> -3'	cEt
	Elution	ISIS404130: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	2'-α-fluoro
		XL168D: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	DNA
		ISIS582801: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	cEt
		ISIS390896: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	LNA
		XL169R: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	2'-O Methyl
		ISIS116847: 5'- <b>CTGCTAGCCTCTGGATTGA</b> -3'	MOE
		XL209-1: 5'- <u>CUGCUCAGCCUCUGGAUUUGA</u> -3'	RNA
		XL183: 5'- <u>CUGCUCAGCCUCUGGAUUUGA</u> -3'	RNA
1E	Capture	ISIS586183: 5'- biotin – <b>CTGCTAGCCTCTGGATTGA</b> -3'	cEt
	Elution	ISIS622870: 5'- <b>CTGCTAGCCTCTGGA</b> -3'	cEt
		ISIS622869: 5'- <b>CTGCTAGCCTCTGGA</b> -3'	cEt
		ISIS622865: 5'- <b>CTGCTAGCCTCTGGA</b> -3'	cEt
		ISIS617421: 5'- <b>CTGCTAGCCTCTGGA</b> -3'	cEt
1F	Capture	ISIS586183: 5'- biotin – <b>CTGCTAGCCTCTGGATTGA</b> -3'	cEt
	Elution	ISIS617421: 5'- <b>CTGCTAGCCTCTGGA</b> -3'	cEt
		ISIS622866: 5'- <b>CTGCTAGCCTCTG</b> -3'	cEt
		ISIS622867: 5'- <b>CTGCTAGCCTC</b> -3'	cEt
		ISIS622868: 5'- <b>CTGCTAGCC</b> -3'	cEt

**Table 2. ASOs for localization**

Figure	ASO Sequence	2' Modification
3A, 3B, 3C, 4A, 4E, 5A, 5B, 5C, S2, S3, S4, S5, and S6	ISIS446654: 5'- Cy3- <b>CTGCTAGCCTCTGGATTGA</b> -3'	MOE
6A, 7 and S9	ISIS454395: 5'-Fluorescein- <b>GCTGATTAGA-GAGAGGTCCC</b> -3' (mixed backbone with 1 PO, indicated by -)	MOE
S8	ISIS652721: 5'- Cy3- <b>ATGGGCTCTGGAACAAGCAT</b> -3'	MOE

Sequences and modifications of ASOs tested in Fig. S3A, S4A, and S6B are listed in the Figures.

**Table 3. Other ASOs**

Figure	Target	ASO Sequence	2' Modification
2B, 6B, 6C, and 6H	NCL1	ISIS110074: 5'- <b>GTCATCGTCATCCTCATCAT</b> -3'	MOE
2B, 6B, and 6C	U16 snoRNA	ISIS462026: 5'- <b>CAGCAGGCAACTGTCGCTGA</b> -3'	MOE
2D	<i>Malat1</i> lncRNA	ISIS395254: 5'- <b>GGCATATGCAGATAATGTTC</b> -3'	MOE
6B, 6D, 6E, 6G, 6H and S6D	<i>NEAT1</i> lncRNA	ISIS407248: 5'- <b>ATGGGCTCTGGAACAAGCAT</b> -3'	MOE
6H	<i>NEAT1</i> lncRNA	ISIS407279: 5'- <b>TTAGGTCTTGTTCCTCAAAC</b> -3'	MOE

6B, 6D, 6E, 6G, 6H,6I and 6J	no target control	ISIS141923: 5'- <b>CCTTCCTGAAGGTTCTCC</b> -3'	MOE
S1	Drosha mRNA	ISIS25690: 5'- <b>ATCCCTTTCTTCCGCATGTG</b> -3'	MOE
S1	PTEN mRNA	ISIS116847: 5'- <b>CTGCTAGCCTCTGGATTTGA</b> -3'	MOE

#### Oligonucleotides and primers:

**Table 4. RNA sequences for ASO/RNA duplex-binding protein isolation**

In the table below, “m” indicates 2'-O-methyl modification, “r” indicates ribose, and underlined sequence indicates RNase I cleavage linker.

RNA	Sequence
XL180	5'- biotin- <u>rArGrCrArGrUrUr</u> CmUmCmAmAmAmUmCmCmAmGmAmGmGmCmUmAmGmCmAmG -3'
XL181	5'- biotin- <u>rArGrCrArGrUrUr</u> CmGmUmGmAmUmGmGmGmUmUmUmGmUmCmUmGmCmGmCmU -3'

**Table 5. Primer-probe sets for qRT-PCR**

Target	Sequence
P54nrb	Forward: 5'- GATTTGGCTTTATCCGCTTGG -3' Reverse: 5'- ACACATACTGAGGAAGGTTTCG -3' Probe: 5'- TTGGCAATCTCCGCTAGGGTTCG -3'
LRPPRC	Forward: 5'- AGGACCGACGGAAGCTGTT -3' Reverse: 5'- AATGCTCCTCCTTGGCCTGTA -3' Probe: 5'- TTCTTTATAACTTGATTGACAGCATGAG -3'
NCL1	Forward: 5'- GCTTGGCTTCTTCTGGACTCA -3' Reverse: 5'- TCGCGAGCTTACCATGA -3' Probe: 5'- CGCCACTTGTCCGCTTCACTCC -3'
U16 snoRNA	Forward: 5'- CTTGCAATGATGTCGTAATTTGC -3' Reverse: 5'- TCGTCAACCTTCTGTACCAGCTT -3' Probe: 5'- TTA CTCTGTTCTCAGCGACAGTTGCCTGC -3'
<i>MALAT1</i> lncRNA	Forward: 5'- AAAGCAAGGTCTCCCACAAG -3' Reverse: 5'- TGAAGGGTCTGTGCTAGATCAAAA -3' Probe: 5'- TGCCACATCGCCACCCCGT -3'
5'- <i>hNEAT1</i> ( <i>NEAT1_1&amp;1_2</i> )	Forward: 5'- TGGTAAGCCCGGGACAGTAA -3' Reverse: 5'- CAGCGGAAGGCTCTCT -3' Probe: 5'- CCGAGTGGCTGTTGGAGTCGGTATTG -3'
3'- <i>hNEAT1</i> ( <i>NEAT1_2</i> )	Forward: 5'- AGTACCCTGAGAGCCAGTATTGGT -3' Reverse: 5'- GGCAGCTGAGTCAATCTCCTTT -3' Probe: 5'- CAGCACTGAGAACCAGGAACGG -3'
5'- <i>mNEAT1</i> ( <i>NEAT1_1&amp;1_2</i> )	Forward: 5'- TGAGCCATGCCTTCAAAACAC -3' Reverse: 5'- TAAATAAGCAAACCTGTTGTCTTC -3'

	Probe: 5'- TCTTGAATTTCTGGAATTGGCC -3'
3'-mNEAT1 (NEAT1_2)	Forward: 5'- ACGGACTTACATTTCCAAGCC -3' Reverse: 5'- ACACATACTGAGGAAGGTTTCG -3' Probe: 5'- AGCAGGAGTCTTCCAGGGCAC -3'
Pre-hNEAT1	Forward: 5'- TGCTTTTACCTTCCCATCTG -3' Reverse: 5'- CAACACTGCGGGGACTCG -3' Probe: 5'- CGCCTTTTGCTTTTCTGCTCACTC -3'
PTEN mRNA	Forward: 5'-AATGGCTAAGTGAAGATGACAATCAT Reverse: 5'-TGCACATATCATTACACCAGTTCGT Probe: TTGCAGCAATTCAGTAAAGCTGGAAAGG
Drosha mRNA	Forward: 5'- CAAGCTCTGTCCGTATCGATCA Reverse: 5'- TGGACGATAATCGGAAAAGTAATCA Probe: 5'-CTGGATCGTGAACAGTTCAACCCCGAT
KHSRP mRNA	Forward: 5'-TTCTCAACTTGGACCCATCC-3' Reverse: 5'-CCACCGCAATCTGTACTTTG-3' Probe: 5'-TGTTAATTTGTTACCTCCTCTGCCCC-3'

**Table 6. Primers for FISH probe sub-cloning**

In the table below, underlined italics indicate T7 promoter sequence

Target	Sequence
5'-hNEAT1 (NEAT1_1&1_2)	Forward: 5'- TAGTTGTGGGGGAGGAAGTG -3' Reverse: 5'- <u>TAATACGACTCACTATAGGGT</u> GGGCATGGACAAGTTGAAGA -3'
3'-hNEAT1 (NEAT1_2)	Forward: 5'- GTCTTTCCATCCACTCACGTCTATTT -3' Reverse: 5'- <u>TAATACGACTCACTATAGGGC</u> ACCCTAACTCATCTTACAGACCACCAG -3'
5'-mNEAT1 (NEAT1_1&1_2)	Forward: 5'- CTGCTGTCTGCTGGCACTTG -3' Reverse: 5'- <u>TAATACGACTCACTATAGGGC</u> CAAGACTTGCGCCTTCAAT -3'
3'-mNEAT1 (NEAT1_2)	Forward: 5'- GCTACTAACACTGAGATCATG -3' Reverse: 5'- <u>TAATACGACTCACTATAGGGC</u> TGAGGTTTGTGGACTGCCAGG -3'

## SUPPLEMENTAL FIGURE LEGENDS

**Figure S1. Depletion of nuclear-localized PS-ASO-associated proteins NCL1 and KHSRP has no effect on antisense activity of ASOs. A.** Reduction of NCL1 and KHSRP mRNAs by corresponding siRNAs as determined by qRT-PCR analysis. UTC, mock treated control cells. **B.** Depletion of NCL1 or KHSRP has no effect on ASO-mediated cleavage of Drosha mRNA as determined by qRT-PCR analysis. **C.** Depletion of NCL1 or KHSRP has no effect on ASO-mediated cleavage of U16 snoRNA as determined by qRT-PCR

analysis. **D.** Depletion of NCL1 or KHSRP has no effect on ASO-mediated cleavage of PTEN mRNA as determined by qRT-PCR analysis.

**Figure S2. PS-ASOs can co-localize with transiently expressed exogenous GFP-P54nrb.** HeLa cells transiently expressing GFP-P54nrb (RG226567, ORIGENE) were transfected with 60 nM fluorescently tagged PS-ASO (ISIS446654). Live-cell images were acquired 4 hrs post ASO transfection. Red and yellow arrows indicate PS bodies and paraspeckles, respectively.

**Figure S3. ASOs with different sequences and chemical modifications localize to paraspeckles or paraspeckle-like foci in multiple tested cell lines. A.** Co-localization of different ASOs with P54nrb to paraspeckles/paraspeckle-like foci in HeLa cells. Backbone modification, 2'-moiety, and sequences of the tested ASOs are indicated. PS-ASOs were transfected at a final concentration of 60 nM for 6hrs. **B.** Co-localization of PS-ASO ISIS446654 with P54nrb (arrows) to nuclear paraspeckles/paraspeckle-like foci was observed in different mouse cell lines including hepatocytes, MEF, bEND, and MHT.

**Figure S4. ASOs with different sequences and chemical modifications localize to perinucleolar caps in multiple tested cell lines. A.** Co-localization of different ASOs with P54nrb to perinucleolar caps in HeLa cells in the presence of actinomycin D (1.5  $\mu\text{g}/\text{mL}$ , 1.5 h). Backbone modification, 2'-moiety, and sequences of the tested ASOs are indicated. PS-ASOs were transfected at a final concentration of 60 nM for 6hrs. **B.** PS-ASO ISIS446654 co-localized with P54nrb (arrows) to perinucleolar caps upon actinomycin D treatment (1.5  $\mu\text{g}/\text{mL}$ , 1.5 h) was observed in multiple tested cell lines including mouse MHT, human A431, and mouse ESCs. Oct-4 served as a marker for mESCs.

**Figure S5. Transcriptional inhibition has no effect on PS body integrity.** IF staining was performed for P54nrb and TCP1- $\beta$  in HeLa cells transfected with 60 nM PS-ASO (ISIS446654) and then treated with actinomycin D (1.5  $\mu\text{g}/\text{mL}$ , 1.5 h). DNA was stained with DAPI. White and yellow arrows indicate perinucleolar caps and PS bodies, respectively.

**Figure S6. Co-localization of PS-ASOs with P54nrb in nuclear ASO-induced filaments was observed for ASOs with different sequences and chemical modifications in multiple tested cell lines. A.** PS-ASO ISIS446654, delivered to mESCs by electroporation, also formed nuclear filament structure, as exemplified by three different cells. **B.** Co-localization of different ASOs with P54nrb to nuclear





filaments in HeLa cells. Backbone modification, 2'-modification, and sequences of the tested ASOs are indicated. PS-ASOs were transfected at a final concentration of 60 nM for 6 hrs. **C.** Co-localization of PS-ASO ISIS446654 with P54nrb (arrows) to nuclear filaments was observed in different tested mouse cell lines including hepatocytes, MHT, and bEND. Paraspeckle protein P54nrb also localizes to ASO-filaments as exemplified in mouse bEND cells. **D.** Formation of P54nrb-containing nuclear filaments in HeLa cells transfected with 60 nM *NEAT1*-specific ASO ISIS407248 for 6 hrs.

**Figure S7. An average of 3 to 10 paraspeckles per HeLa cells were observed.** A population view of co-IF-staining of P54nrb and RNA-FISH of *NEAT1* RNA (5'-probe) in untreated HeLa cells. An average of 3-10 paraspeckles were observed.


**Figure S8. A *NEAT1*-specific ASO co-localized with P54nrb in distinct nuclear foci in HeLa cells.** IF-staining for P54nrb in HeLa cells transfected with 60 nM Cy3-labeled 5-10-5 PS/MOE-modified *NEAT1*-specific ASOs ISIS625751 showed the co-localization of paraspeckle protein P54nrb with *NEAT1*-ASOs in distinct nuclear foci (yellow arrows).

**Figure S9. Localization of PS-ASOs to paraspeckle-like structures was not affected by the depletion of an essential paraspeckle protein P54nrb.** **A.** IF-staining for PSF in HeLa cells transfected with 60 nM PS-ASO ISIS454395. Co-localization of PS-ASOs with PSF paraspeckle-like structures was observed in a well-transfected cell, while in the other cell transfected with little or no PS-ASOs, enrichment of PSF in distinct foci (canonical paraspeckles) was observed. **B.** IF-staining for PSF in (-) P54nrb-depleted HeLa cells transfected with 60 nM PS-ASO ISIS454395. Co-localization of PS-ASOs with PSF in paraspeckle-like structures was observed in a well-transfected cell, while in the other cell transfected with little or no PS-ASOs, no localization of PSF in canonical paraspeckles was observed.

**Figure S1**




**Figure S2**







# Figure S3

**A**




Backbone modification	2'-moiety	Sequence
P=S	2'-Moe	5'- <u>CTGCTAGCCTCTGGATT</u> TGA-3'
P=S	2'-cEt	5'- <u>CTGCTAGCCTCTGGATT</u> TGA-3'
P=S	2'-H	5'-CTGCTAGCCTCTGGATTGA-3'
P=S	2'-OH	5'-UUGUCUCUGGUCCUACUU-3'
P=S P=O	Moe 2'- $\alpha$ -Flouro 2'-O-Methyl	5'-TTGTCTCTGGCTTACTTAA-3'

**B**



# Figure S4

**A**



Backbone modification	2'-moiety	Sequence
P=S	2'-Moe	5'- <u>CTGCTAGCCTCTGGATTGA</u> -3'
P=S	2'-cEt	5'- <u>CTGCTAGCCTCTGGATTGA</u> -3'
P=S	2'-H	5'- <u>CTGCTAGCCTCTGGATTGA</u> -3'
P=S	2'-OH	5'-UUGUCUCUGGUCCUUACUU-3'
P=S P=O	Moe 2'-α-Flouro 2'-O-Methyl	5'-TTGTCTCTGGTCTTACTTAA-3'

**B**







Figure S5




# Figure S6


## A



## B



## C



## D







Figure S7



**Figure S8**





Figure S9

A



B

